Dostarlimab

Dostarlimab, an anti–PD-1 monoclonal antibody marketed by GSK under the brand name Jemperli, has shown impressive results in mismatch repair–deficient stage ...

• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. • All the news that moves the needle in pharma and biotech. If your trial has come to an end, you can subscribe here.

On how the drug works to treat cancer: This drug is one of a class of drugs called immune checkpoint inhibitors. These are immunotherapy medicines that work not ...

You may click on “Your Choices” below to learn about and use cookie management tools to limit use of cookies when you visit NPR’s sites. If you click “Agree and Continue” below, you acknowledge that your cookie choices in those tools will be respected and that you otherwise agree to the use of cookies on NPR’s sites. NPR’s sites use cookies, similar tracking and storage technologies, and information about the device you use to access our sites (together, “cookies”) to enhance your viewing, listening and user experience, personalize content, personalize messages from NPR’s sponsors, provide social media features, and analyze NPR’s traffic.

Dostarlimab monotherapy induced durable antitumor activity in advanced or recurrent endometrial cancer among patients with mismatch repair ...

Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability–high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): The GARNET study. In total, 153 patients were enrolled in cohort A1 and 161 patients in cohort A1, of which 143 patients and 156 patients were evaluable for efficacy, respectively. The median duration of response (DOR) was not reached (NR; range, 1.18+ to 47.21+) in cohort A1, and was 19.4 months (range, 2.8-47.18+) in cohort A2. At the annual meeting, Oaknin reported on the efficacy and safety of dostarlimab monotherapy in 2 expansion cohorts from the GARNET study that enrolled patients with advanced/recurrent endometrial cancer—in particular, from the third pre-specified interim analysis. Both indications are approved under accelerated approval based on tumor response rate and durability of response. “For patients with disease progression that occurs on or after first-line therapy, overall survivor is typically less than 1 year and there is no standard second-line therapy. Similarly, time to PR in both cohorts were 2.69 months and 2.79 months. J Clin Oncol. 2022;40(suppl 16):5509. doi:10.1200/JCO.2022.40.16_suppl.5509 Median overall survival (OS) for cohort A1 was NR (95% CI, 27.1-NR), with a probability of OS at 24 months of 60.5% (95% CI, 51.5%-68.4%), compared with a median OS of 16.9 months (95% CI, 13.0-21.8) and probability of 38.4% (95% CI, 32.0%-44.6%) in cohort A2. In cohort A1, median progression-free survival (PFS) was 6.0 months (95% CI, 4.1-18.0), with a probability for PFS at 24 months of 40.1% (95% CI, 31.6%-48.4%). In cohort A2, median PFS was 2.7 months (95% CI, 2.6-2.8), with a probability of 9.4% for PFS at 24 months (95% CI, 5.2%-15.0%). In the trial, patients with endometrial cancer were enrolled in cohort A1 (dMMR/MSI-H) or cohort A2 (MMRp/MSS). Median follow-up for both cohorts was 27.6 months and 33.0 months, respectively. Dostarlimab (Jemperli) monotherapy induced durable antitumor activity in advanced or recurrent endometrial cancer among patients with mismatch repair deficient (dMMR)/microsatellite instability–high (MSI-H) or mismatch repair proficient (MMRp)/mismatch stable (MSS) disease, according to data from 2 expansion cohorts in the GARNET trial (NCT02715284) presented at the 2022 ASCO Annual Meeting.

In a small clinical trial, 18 patients took the drug Dostarlimab for six months, and all of them had their cancer vanished.

"It is noteworthy that they were all in similar stages of their cancer. According to doctors, the patients, during the trial, took Dostarlimab every three weeks for six months. According to the New York Times, individuals in the clinical experiment previously received treatments such as chemotherapy, radiation, and invasive surgery, all of which could cause bowel, urinary, and sexual dysfunction.

In a clinical trial in the United States, all the participating rectal cancer patients were cured. The medical marvel took place in the country's famous ...

The overall five-year survival rate for rectal cancer is 63 per cent. The rectum is a part of the body's elaborate digestive system. In a clinical trial in the United States, all the participating rectal cancer patients were cured.

The doctor behind a breakthrough New York City-based cancer study said that the astounding results are unlike anything he — or anyone — has seen before, as.

Usually, patients with rectal cancer must endure surgery and chemotherapy — but there was no need for either of those after patients took the drug. The results that have their physicians equally as excited, and ready to see how else this drug could help. Doctors want to repeat the results with a larger group, saying its too early to say that the cancer is permanently gone. The patients — 19 in all, including six more that were included Monday and another one Tuesday — participated in a small clinical trial through Manhattan’s Memorial Sloan Kettering. Each had a specific form of rectal cancer, and took an experimental cancer drug called Dostarlimab. The patients don’t need convincing though. Now, all of the 19 are in complete remission, cancer-free with minimal side-effects.

In the first time in history, a small clinical trial in the United States showed 100% eradication of the cancer disease in patients at the Memorial Sloan ...

The average price of a pint of beer in Britain has increased to £3.95 this year from £2.30 in 2008, the FT cited CGA as saying. Notably, all the patients were in the similar stages of cancer and had not spread to other organs. As per experts, cancer is undetectable by physical exam - proving that the drug could be a potential cure for the disease. 3. According to experts, the drug ‘Dostarlimab’ includes laboratory-produced molecules and acts as substitute antibodies in the human body. The patients had reportedly undergone the US trial expecting to have to go through other procedures in the next step. 2. As per the NYT, the 18 patients had undergone various treatments before for cancer including chemotherapy, radiation, and invasive surgery.

Dostarlimab is a drug which is being used for the treatment of cancer of the uterus lining (endometrial cancer). Read on to know more about this drug.

Reportedly, all 18 rectal cancer patients were given the same drug and as a result of the treatment, cancer was completely obliterated in every patient. what is it being used for? - News

Scientists have reacted with excitement – and a typical splash of caution – to the news that every single cancer patient in a small clinical trial conducted ...

This turns the immune system back on and the T cells are able to find and attack the cancer cells. They stop the proteins on the cancer cells from pushing the stop button. On average, one in five patients have some sort of adverse reaction to checkpoint inhibitors. These can switch off T cells, when they should really be attacking the cancer cells. But to have 100 per cent remission across all patients is unprecedented and cause for great optimism. Patients received the medication every weeks over a six-month period.